SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?


To: Steve Fancy who wrote (5116)8/12/1998 11:42:00 AM
From: Steve Fancy  Respond to of 6136
 
Agouron Pharma's Viracept Gets Canadian Mktg Approval

Dow Jones Newswires

LA JOLLA, Calif. -- Agouron Pharmaceuticals Inc.
(AGPH) received a notice of compliance for its Viracept
HIV protease inhibitor from the Canadian Health
Protection Branch.

In a press release Wednesday, the company said the
notice allows it to market the drug in Canada for the
treatment of HIV infection in combination with reverse
transcriptase inhibitors.

Viracept is approved for marketing in more than 30
countries worldwide.

Agouron Pharmaceuticals develops treatments for
cancer, AIDS, and other diseases.